Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRSTS2021: Risk Adapted Study in Non-Rhabdomyosarcoma Soft Tissue Sarcoma
NCT06239272Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Mar 2024
- Primary completion
- Jun 2034
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor, pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), sponsored by St. Jude Children's Research Hospital. Started Mar 2024; status: recruiting.
02
Drugs
selinexorpazopanib
03
Conditions
non-rhabdomyosarcoma soft tissue sarcoma (NRSTS)
Beyond the preview
Go deeper on NCT06239272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239272.